Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Preliminary Pharmacodynamics of Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy in Patients With Relapsed/Refractory Autoimmune Diseases

NCT07490275 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07490275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07490275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Preliminary Pharmacodynamics of Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy in Patients With Relapsed/Refractory Autoimmune Diseases
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
December 31, 2028
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory / relapsed / progressive systemic sclerosis, refractory / relapsed anti-neutrophil cytoplasmic antibody (anca)-associated vasculitis, refractory / relapsed connective tissue disease-associated thrombocytopenia, refractory / relapsing / progressive inflammatory myopathy, refractory/relapsed systemic lupus erythematosus